Literature DB >> 26714851

The glucocorticoid receptor: cause of or cure for obesity?

Kezia John1, Joseph S Marino2, Edwin R Sanchez3, Terry D Hinds4.   

Abstract

Glucocorticoid hormones (GCs) are important regulators of lipid metabolism, promoting lipolysis with acute treatment but lipogenesis with chronic exposure. Conventional wisdom posits that these disparate outcomes are mediated by the classical glucocorticoid receptor GRα. There is insufficient knowledge of the GC receptors (GRα and GRβ) in metabolic conditions such as obesity and diabetes. We present acute models of GC exposure that induce lipolysis, such as exercise, as well as chronic-excess models that cause obesity and lipid accumulation in the liver, such as hepatic steatosis. Alternative mechanisms are then proposed for the lipogenic actions of GCs, including induction of GC resistance by the GRβ isoform, and promotion of lipogenesis by GC activation of the mineralocorticoid receptor (MR). Finally, the potential involvement of chaperone proteins in the regulation of adipogenesis is considered. This reevaluation may prove useful to future studies on the steroidal basis of adipogenesis and obesity.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  adipogenesis; adipose differentiation; glucocorticoid receptor; glucocorticoid receptor-α; glucocorticoid receptor-β; glucocorticoids; lipolysis

Mesh:

Substances:

Year:  2015        PMID: 26714851      PMCID: PMC4838130          DOI: 10.1152/ajpendo.00478.2015

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  73 in total

1.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Authors:  E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  Wnt/β-catenin signaling pathway and lipolysis enzymes participate in methylprednisolone induced fat differential distribution between subcutaneous and visceral adipose tissue.

Authors:  Xinhua Xiao; Han Li; Jiaojiao Yang; Xiaoyan Qi; Xuyu Zu; Jing Yang; Jing Zhong; Renxian Cao; Jianghua Liu; Gebo Wen
Journal:  Steroids       Date:  2014-03-20       Impact factor: 2.668

3.  Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site.

Authors:  M Adams; M J Reginato; D Shao; M A Lazar; V K Chatterjee
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

4.  Decreased adipogenesis and adipose tissue in mice with inactivated protein phosphatase 5.

Authors:  Wright Jacob; Doron Rosenzweig; Cristina Vázquez-Martin; Suzanne L Duce; Patricia T W Cohen
Journal:  Biochem J       Date:  2015-02-15       Impact factor: 3.857

5.  Association of glucocorticoid receptor polymorphism A3669G in exon 9beta with reduced central adiposity in women.

Authors:  Akheel A Syed; Julie A E Irving; Christopher P F Redfern; Andrew G Hall; Nigel C Unwin; Martin White; Raj S Bhopal; Jolanta U Weaver
Journal:  Obesity (Silver Spring)       Date:  2006-05       Impact factor: 5.002

6.  Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma.

Authors:  E Hu; J B Kim; P Sarraf; B M Spiegelman
Journal:  Science       Date:  1996-12-20       Impact factor: 47.728

7.  Stimulation of lipolysis in humans by physiological hypercortisolemia.

Authors:  G D Divertie; M D Jensen; J M Miles
Journal:  Diabetes       Date:  1991-10       Impact factor: 9.461

Review 8.  Cardiovascular and metabolic impact of glucocorticoid replacement therapy.

Authors:  Gudmundur Johannsson; Oskar Ragnarsson
Journal:  Front Horm Res       Date:  2014-06-10       Impact factor: 2.606

9.  Adipocyte death, adipose tissue remodeling, and obesity complications.

Authors:  Katherine J Strissel; Zlatina Stancheva; Hideaki Miyoshi; James W Perfield; Jason DeFuria; Zoe Jick; Andrew S Greenberg; Martin S Obin
Journal:  Diabetes       Date:  2007-09-11       Impact factor: 9.461

10.  Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21.

Authors:  Terry D Hinds; Komal Sodhi; Charles Meadows; Larisa Fedorova; Nitin Puri; Dong Hyun Kim; Stephen J Peterson; Joseph Shapiro; Nader G Abraham; Attallah Kappas
Journal:  Obesity (Silver Spring)       Date:  2013-12-02       Impact factor: 5.002

View more
  52 in total

1.  Chronic Ethanol Consumption Alters Glucocorticoid Receptor Isoform Expression in Stress Neurocircuits and Mesocorticolimbic Brain Regions of Alcohol-Preferring Rats.

Authors:  Hasan Alhaddad; Darren M Gordon; Richard L Bell; Erin E Jarvis; Zachary A Kipp; Terry D Hinds; Youssef Sari
Journal:  Neuroscience       Date:  2020-04-27       Impact factor: 3.590

2.  Biliverdin Reductase A Attenuates Hepatic Steatosis by Inhibition of Glycogen Synthase Kinase (GSK) 3β Phosphorylation of Serine 73 of Peroxisome Proliferator-activated Receptor (PPAR) α.

Authors:  Terry D Hinds; Katherine A Burns; Peter A Hosick; Lucien McBeth; Andrea Nestor-Kalinoski; Heather A Drummond; Abdulhadi A AlAmodi; Michael W Hankins; John P Vanden Heuvel; David E Stec
Journal:  J Biol Chem       Date:  2016-10-10       Impact factor: 5.157

3.  Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.

Authors:  Terry D Hinds; Peter A Hosick; Shujuan Chen; Robert H Tukey; Michael W Hankins; Andrea Nestor-Kalinoski; David E Stec
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-01-17       Impact factor: 4.310

4.  Genetic variants in the glucocorticoid pathway genes and birth weight.

Authors:  Michael O Schneider; Theresa Hübner; Jutta Pretscher; Tamme W Goecke; Judith Schwitulla; Lothar Häberle; Johannes Kornhuber; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Eva Schwenke
Journal:  Arch Gynecol Obstet       Date:  2020-09-04       Impact factor: 2.344

Review 5.  Endogenous Glucocorticoid Signaling in the Regulation of Bone and Marrow Adiposity: Lessons from Metabolism and Cross Talk in Other Tissues.

Authors:  Anuj K Sharma; Xingming Shi; Carlos M Isales; Meghan E McGee-Lawrence
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

6.  Early weaning leads to specific glucocorticoid signalling in fat depots of adult rats.

Authors:  Rosiane Aparecida Miranda; Carla Bruna Pietrobon; Iala Milene Bertasso; Vanessa S Tavares Rodrigues; Bruna Pereira Lopes; Camila Calvino; Elaine de Oliveira; Egberto Gaspar de Moura; Patrícia C Lisboa
Journal:  Endocrine       Date:  2019-09-07       Impact factor: 3.633

7.  Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor α.

Authors:  Darren M Gordon; Kari L Neifer; Abdul-Rizaq Ali Hamoud; Charles F Hawk; Andrea L Nestor-Kalinoski; Scott A Miruzzi; Michael P Morran; Samuel O Adeosun; Jeffrey G Sarver; Paul W Erhardt; Robert E McCullumsmith; David E Stec; Terry D Hinds
Journal:  J Biol Chem       Date:  2020-05-13       Impact factor: 5.157

8.  Hepatic Glucocorticoid Receptor Plays a Greater Role Than Adipose GR in Metabolic Syndrome Despite Renal Compensation.

Authors:  Sandip K Bose; Irina Hutson; Charles A Harris
Journal:  Endocrinology       Date:  2016-10-18       Impact factor: 4.736

9.  Gene expression effects of glucocorticoid and mineralocorticoid receptor agonists and antagonists on normal human skeletal muscle.

Authors:  Jessica A Chadwick; J Spencer Hauck; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Jill A Rafael-Fortney
Journal:  Physiol Genomics       Date:  2017-04-21       Impact factor: 3.107

10.  Exacerbated obesogenic response in female mice exposed to early life stress is linked to fat depot-specific upregulation of leptin protein expression.

Authors:  Jacqueline R Leachman; Mathew D Rea; Dianne M Cohn; Xiu Xu; Yvonne N Fondufe-Mittendorf; Analia S Loria
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-08-24       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.